Treatment of Cytomegalovirus Retinitis with Intravitreous Cidofovir in Patients with AIDS: A Preliminary Report

Annals of Internal Medicine

Volumn 125, Issue 2, 1996, Pages 98-103

  Rahhal, Firas M ^b   Arevalo, J Fernando ^a   De La Paz, Eugenio Chavez ^a   Munguia, David ^a   Azen, Stanley P ^c   Freeman, William R ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b WEILL CORNELL MEDICAL CENTER   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CIDOFOVIR; CYTOSINE; DRUG DERIVATIVE; ORGANOPHOSPHORUS COMPOUND; PHOSPHONIC ACID DERIVATIVE;

ADULT; AIDS RELATED COMPLEX; ARTICLE; CYTOMEGALIC INCLUSION BODY DISEASE; DISEASE COURSE; FEMALE; HUMAN; INTRALESIONAL DRUG ADMINISTRATION; MALE; MIDDLE AGED; PROSPECTIVE STUDY; RETINITIS; TREATMENT OUTCOME; VIROLOGY; VITREOUS BODY;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; CYTOSINE; DISEASE PROGRESSION; FEMALE; HUMANS; INJECTIONS, INTRALESIONAL; MALE; MIDDLE AGED; ORGANOPHOSPHORUS COMPOUNDS; PHOSPHONIC ACIDS; PROSPECTIVE STUDIES; RETINITIS; TREATMENT OUTCOME; VITREOUS BODY;

EID: 0030585901     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-125-2-199607150-00003     Document Type: Article

References (25)

1. Hoover DR, Saah AJ, Bacellar H, Phair J, Detels R, Anderson R, et al. Clinical manifestations of AIDS in the era of pneumocystis prophylaxis. Multicenter AIDS Cohort Study. N Engl J Med. 1993;329:1922-6.
2. Palestine AG, Stevens G Jr, Lane HC, Masur H, Fujikama LS, Nussenblatt RB, et al. Treatment of cytomegalovirus retinitis with dihydroxy propoxymethyl guanine. Am J Ophthalmol. 1986;101:95-101.
3. Henderly DE, Freeman WR, Causey DM, Rao NA. Cytomegalovirus retinitis and response to therapy with ganciclovir. Ophthalmology. 1987;94:424-34.
4. Mortality in patients with acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. Studies of the Ocular Complications of AIDS Research Group, in collaboration with the AIDS Clinical Trials Group. N Engl J Med. 1992;326:213-20.
5. Palestine AG, Polis MA, De Smet MD, Baird BF, Falloon J, Kovacs JA, et al. A randomized controlled clinical trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS. Ann Intern Med. 1991;115: 665-73.
6. Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial. 4. Visual outcomes. Studies of Ocular Complications of AIDS Research Group, in collaboration with the AIDS Clinical Trials Group. Ophthalmology. 1994;101:1250-61.
7. Flores-Aguilar M, Kuppermann BD, Quiceno JI, Dankner WM, Wolf DG, Capparelli EV, et al. Pathophysiology and treatment of clinically resistant cytomegalovirus retinitis. Ophthalmology. 1993;100:1022-31.
8. Kuppermann BD, Flores-Aguilar M, Quiceno JI, Rickman LS, Freeman WR. Combination ganciclovir and foscarnet in the treatment of clinically resistant cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome. Arch Ophthalmol. 1993;111:1359-66.
9. Treatment of serious cytomegalovirus infections with 9-(1,3-dihydroxy-2-propoxymethyl)guanine in patients with AIDS and other immunodeficiencies. Collaborative DHPG Treatment Study Group. N Engl J Med. 1986;314:801-5.
10. Fanning MM, Read SE, Benson M, Vas S, Rachlis A, Kozousek V, et al. Foscarnet therapy of cytomegalovirus retinitis in AIDS. J Acquir Immune Defic Syndr. 1990;3:472-9.
11. Heinemann MH. Long-term intravitreal ganciclovir therapy for cytomegalovirus retinotherapy. Arch Ophthalmol. 1989;107:1767-72.
12. Cochereau-Massin I, Lehoang P, Lautier-Frau M, Zazoun L, Marcel P, Robinet M, et al. Efficacy and tolerance of intravitreal ganciclovir in cytomegalovirus retinitis in acquired immune deficiency syndrome. Ophthalmology. 1991;98:1348-53.
13. Diaz-Llopis M, Espana E, Munoz G, Navea A, Chipont E, Cano J, et al. High dose intravitreal foscarnet in the treatment of cytomegalovirus retintis in AIDS. Br J Ophthalmol. 1994;78:120-4.
14. Martin DF, Parks DJ, Mellow SD, Ferris FL, Walton RC, Remaley, MA, et al. Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant. A randomized controlled clinical trial. Arch Ophthalmol. 1994;112:1531-9.
15. Anand R, Nightingale SD, Fish RH, Smith TJ, Ashton P. Control of cytomegalovirus retinitis using sustained release of intraocular ganciclovir. Arch Ophthalmol. 1993;111:223-7.
16. Freeman WR, Quiceno JI, Crapotta JI, Listhaus A, Munguia D, Aguilar MF. Surgical repair of rhegmatogenous retinal detachment in immunosuppressed patients with cytomegalovirus retinitis. Ophthalmology. 1992;99:466-74.
17. De Clercq E, Holy A, Rosenberg I, Sakuma T, Balzarini J, Maudgal PC. A novel selective broad-spectrum anti-DNA virus agent. Nature. 1986;323:454-7.
18. Neyts J, Snoeck R, Schols D, Balzarini J, De Clercq E. Selective inhibition of human cytomegalovirus DNA synthesis by (S)-1-(3-hydroxy-2-phosphonyl-methoxypropyl) cytosine [(S)-HPMPC] and 9-(1,3-dihydroxy-2-propoxymethyl) guanine (DHPG). Virology. 1990;179:41-50.
19. Snoeck R, Sakuma T, De Clercq E, Rosenberg I, Holy A. (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine, a potent and selective inhibitor of human cytomegalovirus. Antimicrob Agents Chemother. 1988;32:1839-44.
20. Kirsch LS, Arevalo JF, De Clercq E, Chavez de la Paz E, Munguia D, Garcia R, et al. Phase I/II study of intravitreal cidofovir for the treatment of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome. Am J Ophthalmol. 1996;119:466-76.
21. Kirsch LS, Arevalo JF, Chavez de la Paz E, Munguia D, de Clercq E, Freeman WR. Intravitreal cidofovir (HPMPC) treatment of cytomegalovirus retinitis in patients with acquired immune deficiency syndrome. Ophthalmology. 1995;102:533-43.
22. Studies of ocular complications of AIDS Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial: 1. Rationale, design, and methods. AIDS Clinical Trials Group (ACTG). Controlled Clin Trials. 1992;13:22-39.
23. Studies of the Ocular Complications of AIDS, in collaboration with the AIDS Clinical Trials Group. HPMPC peripheral CMV retinitis trial (HPCRT protocol, version 1.4). The Johns Hopkins University Center for Clinical Trials. Baltimore; January 1995.
24. Lesar T, Fiscella RG. Antimicrobial drug delivery to the eye. Drug Intell Clin Pharm. 1985;19:642-54.
25. Freeman WR, Friedberg DN, Berry C, Quiceno JI, Behette M, Fullerton SC, et al. Risk factors for development of rhegmatogenous retinal detachment in patients with cytomegalovirus retinitis. Am J Ophthalmol. 1993;116: 713-20.